Journal
ONCOIMMUNOLOGY
Volume 3, Issue 9, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/21624011.2014.955684
Keywords
combined therapies; immunomodulation; immunosuppressive pathways; TA-targeting mAbs; vaccine-like effects
Categories
Funding
- INSERM
- Universite de Montpellier 1
- LabEx MabImprove
- Fondation pour la Recherche Medicale (FRM)
Ask authors/readers for more resources
Tumor antigen (TA)-targeting monoclonal antibody (mAb)-based treatments are considered to be one of the most successful strategies in cancer therapy. Besides targeting TAs and inducing tumor cell death, such antibodies interact with immune cells through Fc-dependent mechanisms to induce adaptive memory immune responses. However, multiple inhibitory/immunosuppressive pathways can be induced by tumor cells to limit the establishment of an efficient antitumor response and consequently a sustained clinical response to TA-targeting mAbs. Here, we provide an overview on how TA-targeting mAbs in combination with conventional cancer therapies and/or inhibitors of key immunosuppressive pathways might represent promising approaches to achieve long-term tumor control.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available